Kornimate/medical-research-clean huggingface dataset:
study of the effectiveness of a computer decision support system to improve physicians' screening for autism

Conditions: Healthy Children Undergoing Routine Care; Children With Autism

Summary: the investigators hypothesize that children seen in a clinic that uses a compute based system known as chica, which reminds pediatricians to screen at defined time point for autism, will be screened more consistently for autism and receive more timely diagnostic a treatment services.

to be eligible for this trial, participants must receive their care at one of four primary care clinics in indianapolis where the chica system is used.

Eligibility criteria:
inclusion criteria: * previously healthy children receiving routine care in one of four clinics in indianapolis who participate in this study. exclusion criteria: * previously known autism spectrum disorders or other causes of developmental delay

Keywords: autism well child care screening computer reminders
anisocoria in the intensive care unit (aicu study)

Conditions: Anisocoria

Summary: this retrospective single-center cohort study aims to determine the prevalence of acute "new onset" pupillary abnormalities in adult intensive care unit patients, assess their clinical impact, identify the contexts leading to treatment changes, and evaluate their prognostic implications.

assessment of the pupil symmetry and reactivity to light are important parts of the neurological evaluation of critically ill patients in intensive care units (icus). anisocoria, a condition where the pupils are unequal in size, can be found in up to 60% of patients with acute neurologic injuries. it may indicate serious underlying issues like traumatic brain injury, cerebrovascular accidents, brain tumors or viral encephalitis. however, anisocoria or impaired pupillary reactivity can also be caused from less severe conditions, such as drug effects (e.g., ipratropium bromide),horner's syndrome after central venous cannulation, or intoxications with substances like anticholinergics, opioids, and cannabinoids. despite these well-known causes, there is limited data on the prevalence and clinical consequences of anisocoria in icu patients. new onset of pupillary abnormalities often requires immediate neurological evaluation and neuroimaging (computed tomography (ct) or magnetic resonance imaging (mri)), but many of these scans may not reveal clinically relevant findings and could expose patients to unnecessary risks. this is particularly concerning as benign causes of pupillary abnormalities are common, while more serious conditions can sometimes be overlooked. current studies do not fully address when ct or mri scans are necessary, or when they provide no significant clinical benefit. this retrospective single-center cohort study has four primary objectives: 1. to determine the prevalence of acute "new onset" pupillary abnormalities (anisocoria and/or impaired light-reactive pupillary response) in adult icu patients. 2. to assess the clinical impact of these abnormalities, particularly in terms of the frequency of diagnostic tests like ct or mri scans, and ophthalmologic and neurologic consultations. 3. to identify when pathological findings lead to treatment modifications 4. to evaluate the prognostic implications of these pupillary abnormalities on patient outcomes. the results of this study may improve the understanding of acute pupillary abnormalities in icu patients, helping to optimize diagnostic strategies, reduce unnecessary neuroimaging, and enhance patient safety and outcome prediction.

Eligibility criteria:
inclusion criteria: * adult patients (i.e., patients ≥18 years of age) * reported incident of pupillary abnormality (either anisocoria or non-normal pupillary reactivity) in the intensive care unit at the university hospital basel between 2013-2024. exclusion criteria: * patients younger than 18 years * patients with documented refusal of data use.

Keywords: pupillary abnormality intensive care unit
phase 1/2 study of ucart22 in patients with relapsed or refractory cd22+ b-cell acute lymphoblastic leukemia (balli-01)

Conditions: B-cell Acute Lymphoblastic Leukemia

Summary: this is a first-in-human, open-label, dose escalation and expansion study of ucart22 administered intravenously to patients with relapsed or refractory b-cell acute lymphoblastic leukemia (b-all). the purpose of this study is to evaluate the safety and clinical activity of ucart22 and determine the maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d)


Eligibility criteria:
inclusion criteria: * b-all blast cells expressing cd22 * diagnosed with r/r b-all * prior therapy must include at least one standard chemotherapy regimen and at least one salvage regimen exclusion criteria: -prior cellular therapy or investigational cellular or gene therapy within 90 days prior to enrollment

Keywords: b-cell acute lymphoblastic leukemia (b-all) relapse/refractory b-all universal chimeric antigen receptor t-cell (ucar-t) therapy allogeneic transcription activator-like effector nuclease (talen®)
velacur by sonic incytes for portal hypertension

Conditions: Portal Hypertension; Chronic Advanced Liver Disease

Summary: this is a cross sectional study that evaluates the relationship between lsm (liver stiffness measurement) by liver incytes in patients with cacld (compensated advanced chronic liver disease) and manifestations of portal hypertension.

the purpose of this study is to assess the severity of portal hypertension in people with compensated advanced chronic liver disease (cacld) who have not undergone liver transplant by measuring liver stiffness with the liver incytes device (velacur) and comparing the performance of lsm (liver stiffness measurement) via velcaur and transient elastography via fibroscan to esophageal varices.

Eligibility criteria:
inclusion criteria: 1. adults aged 18 years or older 2. ability to provide informed consent 3. planned standard of care upper endoscopy to screen for varices 4. planned standard of care transjugular liver biopsy with portal pressure measurement exclusion criteria: 1. inability or refusal to provide informed consent 2. fasting for less than three hours prior to the scan 3. subject is a pregnant or lactating female 4. subject with current, significant alcohol consumption 5. patients with a pacemaker or defibrillator 6. acute hepatitis defined as ast/alt \> 500 u/l 7. ascites 8. post liver transplantation
a study of jnj-55308942 in the treatment of bipolar depression

Conditions: Bipolar Disorder

Summary: the purpose of this study is to evaluate the efficacy of jnj-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (bd) in a major depressive episode (mde) at week 6.


Eligibility criteria:
inclusion criteria: * have a primary diagnostic and statistical manual of mental disorders (5th edition) (dsm-5) diagnosis of bipolar disorder (bd) (type i or ii) without current psychotic features, as confirmed by the mini international neuropsychiatric interview (mini) * medically stable on the basis of physical examination, medical history, and vital signs performed at screening. any abnormalities must be consistent with the underlying illness in the study population. this determination must be recorded in the participant's source documents and initialed by the investigator * have a body mass index (bmi) between 18.0 and 35.0 kilograms per meter square (kg/m\^2) inclusive (bmi = weight/height\^2) * a woman of childbearing potential (wocbp) must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin \[beta-hcg\]) at screening and a negative urine pregnancy test before the first dose of study intervention exclusion criteria: * currently meets the dsm-5 criteria for manic episode (me) on the mini * received transcranial magnetic stimulation (tms), any transcranial electrical stimulation, including transcranial direct current stimulation (tdcs), vagal nerve stimulation (vns) and/or deep brain stimulation (dbs) within 6 weeks prior to randomization * history of moderate to severe cannabis misuse according to dsm-5 criteria within 6 months before screening * history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence)
iatrogenic deficiencies in icu patients with prolonged continuous renal replacement therapy

Conditions: Acute Kidney Injury

Summary: icu patients are recruited after at least 5 days treatment with continuous renal replacement therapy. blood samples are drawn at time of recruitment and then every 3-5 days until ceseation of renal replacement therapy. samples will be analyzed for concentrations of trace elements, vitamins and amino acids. 10 adult icu patients treated for two weeks without renal replacement therapy will be sampled at one time point to serve as controls.


Eligibility criteria:
inclusion criteria crrt group: * crrt more than 5 days exclusion criteria: * n/a inclusion criteria non-crrt group - icu care 10-15 days without any dialysis treatment
combination of the immune modulator dimethyl fumarate with intraarterial treatment in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the investigators conduct this study to investigate whether oral administration of dimethyl fumarate, a food and drug administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with acute ischemic stroke.


Eligibility criteria:
inclusion criteria: 1.18-80 years old 2. nihss score\>6 3. for the first stroke, mri showed anterior circulation infarction 4. patients who meet the mechanical thrombectomy treatment by mri assessment within 24 hours exclusion criteria: 1. patients receiving alteplase thrombolysis 2. other diseases of the central nervous system 3. there has been a neurological disability in the past (mrs score\>2) 4. difficulty swallowing 5. arrhythmia, atrioventricular block 6. use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs 7. macular edema 8. magnetic resonance angiography shows vertebra-basilar artery obstruction 9. hemorrhagic stroke 10. patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product 11. pregnant and lactating women

Keywords: acute ischemic stroke immune modulator dimethyl fumarate intraarterial treatment
68ga-ny104 pet/ct in patients with metastasis/recurrence clear cell renal cell carcinoma suspicion

Conditions: Clear Cell Renal Cell Carcinoma

Summary: this is a prospective, single-center, single-arm phase 2 study in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion. the goal is to determine the sensitivity and specificity of 68ga-ny104 pet/ct in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion

this is a prospective, single-center, single-arm phase 2 study in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion. each patient will receive one dose of 68ga-ny104. dedicated whole-body pet/ct imaging will be performed. pet/ct studies will be interpreted by two readers, both of whom will provide independent and blinded interpretations. imaging interpretations and a composite ground truth will be used to estimate the diagnostic efficacy of 68ga-ny104 pet/ct. a total of 40 patients will be recruited at peking union medical college hospital.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 y 2. histopathological diagnosis of clear cell renal cell carcinoma 3. suspected of metastasis or recurrence from ccrcc based on previous conventional imaging or 18f-fdg pet/ct scan. 4. expected survival of at least 6 months 5. ecog ≤ 2 6. written informed consent provided for participation in the trial 7. in the opinion of investigator, willing and able to comply with required study procedures. exclusion criteria: 1. on vegf tki treatment less than 1 week before 68ga-ny104 pet/ct. tki is known to affect girentuximab binding in patients with ccrcc and is expected to have the same effect on 68ga-ny104. if patients were on vegf tki treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68ga-ny104 pet/ct is required. 2. patients on hif antagonist treatment \< 3 months before 68ga-ny104 pet/ct. ca9, which encodes carbonic anhydrase ix (caix), is one of the genes most strongly upregulated by hif-1. hif antagonist, such as belzutifan, might affect the expression of caix and thus the binding of 68ga-ny104 to tumor. withdraw of at least 3 months is required for hif antagonist. 3. pregnancy or breastfeeding. 4. severe claustrophobia.

Keywords: 68ga-ny104 pet/ct clear cell renal cell carcinoma
68ga-nota-prgd2 pet/ct in patients with lung injury and pulmonary fibrosis

Conditions: Pulmonary Fibrosis, Unspecified

Summary: this is an open-label positron emission tomography/computed tomography (pet/ct) study to investigate the diagnostic performance and evaluation efficacy of 68ga-nota-prgd2 in lung injury (li) and pulmonary fibrosis (pf) patients. a single dose of nearly 111 mbq 68ga-nota-prgd2 (≤ 40 µg nota-prgd2) will be intravenously injected into patients with li/pf. visual and semiquantitative method will be used to assess the pet/ct images.

the αvβ3-integrin is a transmembrane heterodimeric receptor that mediates cell-cell and cell-extracellular matrix adhesion. the αvβ3-integrin plays a pivotal role in promoting and sustaining angiogenesis and fibrosis. cyclic arginine-glycine-aspartic acid (rgd) peptide is the key integrin recognition motif that can strongly bind to the αvβ3-integrin, which makes the rgd-based peptides hold a promise for imaging and treatment of diseases characterised with angiogenesis and fibrosis including li and pf. animal study in bleomycin induced lung fibrosis showed good uptake ratio of 68ga-nota-prgd2 in lung vs background. for interests in clinical translation of 68ga-nota-prgd2, an open-label dynamic whole-body pet/ct study was designed to investigate safety and diagnostic performance of 68ga-nota-prgd2 in patients with li or pf.

Eligibility criteria:
inclusion criteria: patients with idiopathic pulmonary fibrosis * males and females, ≥18 years old. * characteristic clinical signs, symptoms and laboratory tests suggesting the diagnosis of li/pf. * the diagnosis of ipf is based on the centres for disease control and prevention (cdc) criteria for diagnosing li/pf. they rely on a combination of clinical, radiological, operative and histological findings, in addition to results of other laboratory tests. exclusion criteria: * females planning to bear a child recently or with childbearing potential. * renal function: serum creatinine \>3.0 mg/dl (270 μm/l). * liver function: any hepatic enzyme level more than 5 times upper limit of normal. * known severe allergy or hypersensitivity to iv radiographic contrast. * patients not able to enter the bore of the pet/ct scanner. * inability to lie still for the entire imaging time because of cough, pain, etc. * inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc. * concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.

Keywords: pet lung injury integrin receptor
impact of cognitive behavioural therapy for insomnia on endocrine therapy adherence

Conditions: Insomnia; Breast Cancer; Adherence, Medication; Quality of Life; Survivorship

Summary: the aim of this study is to investigate the impact of cognitive behavioural therapy for insomnia on adherence to endocrine therapy medication in breast cancer survivors.

approximately 70% of breast cancer cases are hormone-receptor positive, therefore treatable with endocrine therapy medication. when taken as prescribed, this is effective in reducing the risk of breast cancer recurrence following primary treatment. however, research indicates that nonadherence (not taking medication as prescribed, whether due to forgetfulness or deliberately missing a dose) is an issue, with side effects being a consistent predictor of nonadherence. sleep problems are one of the most common endocrine therapy side effects. the aim of this study is to explore the influence of cognitive behavioural therapy for insomnia (cbt-i) on endocrine therapy adherence in breast cancer survivors. participants will be randomised to 1 of 2 groups: intervention, or waitlist control. both groups will complete measures of sleep and other endocrine therapy side effects (depression, anxiety, fatigue, musculoskeletal pain, and vasomotor symptoms) at baseline, post-intervention, and 12-week post-randomisation follow-up. following randomisation, the intervention group will receive 4 weekly group cbt-i sessions remotely through videoconferencing, whereas waitlist control participants will receive the intervention after 12 weeks, once all measures are completed. primary outcome will be self-reported endocrine therapy adherence, with secondary outcomes including insomnia symptoms and other endocrine therapy side effects.

Eligibility criteria:
inclusion criteria: * diagnosed with breast cancer * aged 18 or over * currently prescribed endocrine therapy medication * experience symptoms of insomnia * self-reported nonadherent to et medication (e.g. forgetting to take, or deliberately taking a break from medication) * proficient in english language * access to videoconferencing exclusion criteria: * undertaking shift work (i.e., irregular or night shifts) * pregnancy or breastfeeding * other unstable physical or mental health problem (including substance misuse) * received cbt-i within past 12 months * received chemotherapy or radiotherapy within past 4 weeks
ultrasound guided tap block for postoperative analgesia after abdominal surgery.

Conditions: Postoperative Pain

Summary: transversus abdominis plane (tap) block is a novel type of peripheral nerve block that involves innervations of the anterolateral abdominal wall derived from t6-l1.it provides adequate post-operative pain relieve following the various abdominal surgeries. theoretically, tap block may replace the need for epidural analgesia after abdominal operations. the oblique subcostal approach of the tap (ostap) block, which was de¬scribed by (hebbard et al, 2010) , has been reported to provide analgesia to the entire anterior abdomen.

the transversus abdominis plane (tap) technique, originally described by involves injection of local anaesthetic in the plane between the internal oblique and transversus abdominis muscle layers, with the aim of anaesthetising the intercostal nerves supplying the abdominal wall. initially, the block used surface landmarks of the triangle of petit (latissimus dorsi posteriorly, external oblique superiorly, iliac crest inferiorly) and a double fascial 'pop' (loss of resistance) to guide placement of the local anaesthetic. more recently, ultrasonography has been used to guide the delivery of the injectate into the appropriate plane, thereby increasing the accuracy of the technique. the duration of the tab is limited to effect of administered local anesthetics. to prolong the block's duration, adjuvant medications were added to la to magnify the effect of tap block . opiates such as morphine and tramadol have peripheral and central analgesic effects. opiate receptors are present at the terminals of afferent peripheral nerves; therefore, administration of opiates peripherally might provide a significant analgesic effect.

Eligibility criteria:
inclusion criteria: bmi\< 30kg/m2. * age: 18-60 years. * sex: both males and females. * asa physical status: 1-ii. * operation: abdominal laparotomy. exclusion criteria: * patient refusal. * history of cardiac disease, psychological disorders, respiratory diseases including asthma, renal or hepatic failure. * coagulation disorders. * allergy to study medications. * chronic use of pain medications. * pregnancy. * respiratory tract in-fection within the last 2 weeks. * heavy smoker. * histo-ry of abdominal surgery or trauma.

Keywords: abdominal surgery, pain, local, transversus abdominus block.
sleep apnea and gestational diabetes

Conditions: Gestational Diabetes; Sleep Apnea

Summary: the investigators hypothesize that pregnant women with gestational diabetes will have a high incidence of sleep apnea, and that the treatment of sleep apnea will lead to improved glucose control in these women.


Eligibility criteria:
inclusion criteria: * gestational diabetes exclusion criteria: * pre-gestational diabetes
mandibular first molar distalization

Conditions: Class III Malocclusion

Summary: a clinical study to test the capability of the mini-screws inserted in the mandibular buccal shelf area as an anchorage unit to distalize mandibular first molar for correction of mild to moderate class iii cases. the second aim was to detect if there is a difference in the amount of distalization in the presence of unerupted mandibular third molars, using the same technique.

class iii malocclusion in adults is one of the most complex malocclusions in clinical orthodontics. for adults, the ideal treatment option for class iii malocclusion is accomplished either by camouflage treatment in mild to moderate cases or orthognathic surgery in severe cases. camouflage treatment for class iii malocclusion comprises three main techniques; class iii elastics, mandibular first molar distalization, or extraction of mandibular first premolars. mandibular first molar distalization via the use of skeletal anchorage has the problem of increased failure rate of the inter-radicular temporary anchorage devices (tads). accordingly, a randomized clinical trial using extra radicular tads in the mandibular buccal shelf area was designed in the current research aiming to test the efficacy of such a technique in inducing mandibular molar distalization with decreased failure rate, and whether the presence of unerupted mandibular third molars will affect the distalization movement or not.

Eligibility criteria:
inclusion criteria: * class iii dental incisal relation. * dental canine and molar relation not more than half unit class iii. * presence of unerupted mandibular third molars on both sides. * skeletal class i or mild class iii. * full permanent dentition. * medically free subjects. exclusion criteria: * patients with systemic diseases or neuromuscular disorders. * retroclined lower incisors. * sever skeletal dysplasia. * patients with periodontal disease.

Keywords: class iii malocclusion mandibular buccal shelf mini-screws extra-radicular mini-screws distalization temporary anchorage device